Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

HER2+ Apocrine Carcinoma of the Breast Trends Towards Less Aggressive Phenotype, Favorable Outcomes

April 7, 2022
By Hayley Virgil
Article

Patients with HER2-positive apocrine carcinoma of the breast are less likely to have an aggressive phenotype and are more likely to have favorable outcomes, even though the group has a lower rate of estrogen and progesterone receptor positivity.

Less aggressive phenotypes and favorable outcomes have been observed in HER2-positive apocrine carcinoma (APO) of the breast, even though this population is characterized as having lower rates of estrogen (ER) and progesterone receptor (PR)–positive disease, according to research published in Breast Cancer Research and Treatment.

HER2-positive APO was more common in patients 80 years or older (24.7%) compared with the HER2-positive no special type (NST) cohort (15.7%; P <.001). In the population of patients with steroid receptor (SR)–negative disease, those with APO had significantly lower histological grades compared with the NST cohort (P <.001). Additionally, breast cancer–related death was less notable in the APO group (3.9%) vs the NST group (7.8%; P = .019), especially in the subgroup of patients with SR-negative disease (4.2% vs 10.4%; P <.008); this was further reaffirmed by univariate analysis (P = .03).

“Our findings indicate that [patients with] HER2-positive APO do substantially better compared with HER2-positive NST carcinomas. This is mainly reflected in BCSS [breast cancer–specific survival] and was independent of ER and PR status. Our results are in line with a recently published SEER [Surveillance, Epidemiology, and End Results] cohort of triple-negative APO, which also revealed that these cancers had a better prognosis than [triple-negative breast cancer] NST. Several other independent studies confirmed a more favorable outcome for [patients with] triple-negative APO,” investigators wrote.

Investigators used the SEER database, which included data such as demographics, tumor characteristics, first treatment, treatment options, and follow up, to build a cohort of patients. Patients were selected based on histologically confirmed invasive HER2-positive APO who were diagnosed from 2010 to 2016. Patients were divided based on ER/PR and HER2 status. Those with in situ carcinomas and other certain types of HER2-positive invasive breast carcinomas were excluded.

Of 446,806 patients who were diagnosed with a breast malignancy from 2010 to 2016, 259 had HER2-positive APO. Within the same time period, 52,860 patients were diagnosed with HER2-positive invasive breast cancer NST. The median follow up was 31 months for the pooled cohort, 27 months for the APO cohort, and 31 months for the NST cohort.

Patients had an average age of 69.1 years in the APO cohort vs 65.3 years in the NST cohort (P <.001).

No notable differences were reported between the groups with regard to race, tumor stage, regional lymph node status, or presence of distant metastases. Additionally, treatment options such as surgery and chemotherapy were similar between the groups, although investigators reported that radiotherapy was more commonly used in the APO cohort vs the NST cohort (P = .05).

The APO group also had a higher estimated overall survival (OS) rate at 18 months and beyond compared with the NST group (HR, 1.26; 95% CI, 0.83-1.92), although the difference wasn’t statistically significant (P = .264). Despite this, apocrine morphology has a positive effect, with investigators reporting an unadjusted HR of 1.83 in the BCSS analysis; this translated to an 83% higher hazard of breast cancer–specific death in the NST cohort.

Findings from the multivariate Cox proportional hazards model analysis indicated that the APO cohort had both better OS (HR, 1.512; 95% CI, 0.9-2.32; P = .059) and significantly better BCSS (HR, 2.19; 95% CI, 1.13-4.21; P = .018) vs the NST cohort.

Reference

Skenderi F, Alahmad MAM, Tahirovic E, et al. HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome. Breast Can Res and Treat. Published online March 30, 2022. doi:10.1007/s10549-022-06578-4

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
Related Content

Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

ONCOLOGY Staff
June 19th 2024
Article

Carey K. Anders, MD, spoke about updated findings in the HER2-positive breast cancer space, based on data from 2023 SABCS.


HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

Sara Hurvitz, MD
January 8th 2024
Podcast

Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.


Targeted Therapy Options for HER2+ Breast Cancer

Targeted Therapy Options for HER2+ Breast Cancer

ONCOLOGY Staff
January 13th 2024
Article

A Satellite Session, involving members from US Oncology, focused on treatment options for patients with HER2-positive metastatic breast cancer.


Treatment Combinations for HER2-Positive Breast Cancer

Treatment Combinations for HER2-Positive Breast Cancer

Mark D. Pegram, MD
March 7th 2013
Podcast

As part of our coverage for the 30th Annual Miami Breast Cancer Conference, we bring you an interview with Dr. Mark Pegram, director of the breast cancer program at the Stanford Women’s Cancer Center and codirector of the molecular therapeutics program. Dr. Pegram will be discussing the potential for novel HER2 combination therapies at the conference.


Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.

Tucatinib/T-DM1 Yields ‘Encouraging’ PFS in Unresectable HER2+ Breast Cancer

Russ Conroy
August 31st 2023
Article

Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.


Findings from the phase 3 DESTINY-Breast04 trial supported the approval of fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer in China.

Trastuzumab Deruxtecan Receives Chinese Approval in HER2-Low Breast Cancer

Hayley Virgil
July 15th 2023
Article

Findings from the phase 3 DESTINY-Breast04 trial supported the approval of fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer in China.

Related Content

Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

ONCOLOGY Staff
June 19th 2024
Article

Carey K. Anders, MD, spoke about updated findings in the HER2-positive breast cancer space, based on data from 2023 SABCS.


HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

Sara Hurvitz, MD
January 8th 2024
Podcast

Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.


Targeted Therapy Options for HER2+ Breast Cancer

Targeted Therapy Options for HER2+ Breast Cancer

ONCOLOGY Staff
January 13th 2024
Article

A Satellite Session, involving members from US Oncology, focused on treatment options for patients with HER2-positive metastatic breast cancer.


Treatment Combinations for HER2-Positive Breast Cancer

Treatment Combinations for HER2-Positive Breast Cancer

Mark D. Pegram, MD
March 7th 2013
Podcast

As part of our coverage for the 30th Annual Miami Breast Cancer Conference, we bring you an interview with Dr. Mark Pegram, director of the breast cancer program at the Stanford Women’s Cancer Center and codirector of the molecular therapeutics program. Dr. Pegram will be discussing the potential for novel HER2 combination therapies at the conference.


Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.

Tucatinib/T-DM1 Yields ‘Encouraging’ PFS in Unresectable HER2+ Breast Cancer

Russ Conroy
August 31st 2023
Article

Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.


Findings from the phase 3 DESTINY-Breast04 trial supported the approval of fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer in China.

Trastuzumab Deruxtecan Receives Chinese Approval in HER2-Low Breast Cancer

Hayley Virgil
July 15th 2023
Article

Findings from the phase 3 DESTINY-Breast04 trial supported the approval of fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer in China.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.